Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.
GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people with Parkinson’s disease, according to a new study. Researchers conducted a double-blind,
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The Lancet,
GLP-1 drug exenatide shows no benefit for Parkinson's in new study
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.
GLP-1 Drug Offers Limited Gains for Parkinson's Patients
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was natural for the scientists to be hopeful when they tested the possibility of an Ozempic-like drug to improve Parkinson's disease symptoms,
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.
1d
Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The Lancet
1d
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
The Conversation on MSN
6d
Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big Risks
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Trump bans trans athletes
Blake Lively sued again
Security detail revoked
Thousands protest policies
Trump cases review ordered
DOJ restricts DOGE's access
To boycott G20 meeting
Faces primary challenge
Johnson agrees to testify
Disbands cadet clubs
Newsom meets with Trump
Named the new Aga Khan
FBI agents won't lose jobs
MX troops arrive at border
Ends DEI hiring goals
US deports Indian migrants
Pro-Trump group renamed
Record producer Gotti dies
To accept parcels from China
Second strain in dairy cattle
Reaches tentative deal
Abuse scandal settlement
US private payrolls rise
Blocks citizenship order
Fox News hires Lara Trump
Parked Delta plane struck
Confirmed as HUD secretary
To cut 8.5% of its workforce
Strikes deal on migrants
Matt Kuchar's father dies
Alex Jones bankruptcy case
Judge tosses last charge
Feedback